Eisai announced July 25 that it is incorporating Medidata’s data studio into its clinical trial management platform. “We’ve included Medidata’s Clinical Data Studio in our clinical trial ...

Japanese pharma Eisai ... as Sunrise 1, the experimental sleep and wake regulation drug was pitted against an extended-release form of zolpidem, now a generic, as well as a dummy pill. The trial ...

Following the news of two lecanemab-related deaths reported on the eve of the Clinical Trials on Alzheimer’s Disease (CTAD) 2022 conference, Eisai has now presented the full results from its ...

Additionally, other important research from the lecanemab clinical development program and Eisai's AD pipeline, including the company's investigational anti-microtubule binding region (MTBR ...

Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced Eisai Inc. (“Eisai”), the U.S. pharmaceutical subsidiary of ...

“It is very dangerous to cross-read on trials,” Chief Executive Severin Schwan said in a briefing for reporters on Tuesday. “We have to wait for the readout, and then we can take it from ...